It seems likely that SARIFAs could serve as a biomarker that is not only prognostic but also effective for the selection of tumours that are particularly driven by lipids, what on the other hand could pave the way for new treatment approaches specifically targeting lipid metabolism in SARIFA-positive PDAC, for example, by using metformin, CPT1 or FABP4 inhibitors [16, 46–48]. Here, FABP4 is linked to neoplasm.